Redeye updates its estimates and valuation following Remedy’s H1 report, where we increase our cost estimates.
Redeye comments on Remedys Q2-report. Revenue was somewhat below our estimates while EBIT was clearly below.
Redeye looks beyond the soft result in Q1 and starts looking forward to the strong pipeline of games in 2023-2025.
Redeye comment on Remedy’s Q1 business review. Sometimes milestone payments do not adapt to the quarterly economy so well, which is shown in...
Redeye has postponed the expected release of the free-to-play game codenamed Vanguard in its research update.
Remedy reported a Q4 with revenue of EUR 13.6 million exactly in line with our estimates and an EBIT of EUR 2.
Redeye keeps its valuation range and base case unchanged despite a lowered revenue and EBIT expectation in 2023.
Revenues came in lower than expected during the quarter.
Redeye lowers its expectations and valuation on Remedy.
Redeye will not make any immediate adjustments following the lowered guidance for 2022 from Remedy.
Redeye has done some adjustments after the Q1 result.
Redeye comments on Remedy’s Q1 business review. Revenue was EUR 1.
Redeye updates its financial projections in Remedy Entertainment.
Redeye comment on Remedy’s full-year report. Remedy posted an EBIT result in line with our estimated and somewhat higher revenue than expect...
Redeye comments on Remedy’s stable H1-report. Revenue amounted to EUR 17.
